We are coming to the end of the 60 day open comment period for the FDA’s draft guidance on Duchenne. PPMD submitted our comments to the agency yesterday – click here to read what was submitted. While we hope you agree with our response, we respect alternate viewpoints. If you disagree with any comments or have other issues you think the guidance needs to address, we urge you to submit your opinions as well through the FDA public comment mechanisms. This community-wide effort continues to be acknowledged as precedent setting and a variety of rare disease groups are following in our footsteps. We have so much to be proud of and look forward to next steps with the FDA!